4.4 Article

T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients

Journal

AIDS
Volume 30, Issue 14, Pages 2149-2158

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0000000000001176

Keywords

cytotoxic T lymphocytes; HIV-1; p17 gag; RNA electroporation; SLYNTVATL epitope; T-cell receptor transfer

Funding

  1. DFG German Research Foundation [Graduiertenkolleg 1071]
  2. Hector foundation
  3. DFG - German Research Foundation [HA 2331/2-1]
  4. IZKF Erlangen project [A27]
  5. German Competence Network for HIV/AIDS

Ask authors/readers for more resources

Objectives: Strategies to cure HIV-1 infection require the eradication of viral reservoirs. An innovative approach for boosting the cytotoxic T-lymphocyte response is the transfer of T-cell receptors (TCRs). Previously, we have shown that electroporation of TCR-encoding mRNA is able to reprogram CD8(+) T cells derived from healthy donors. So far, it is unknown whether the transfer of HIV-1-specific TCRs is capable to reprogram CD8(+) T cells of HIV-1-infected patients. To assess the efficiency of TCR-transfer by mRNA electroporation and the functionality of reprogramed T cells in HIV-1-infected patients, we performed an in-vitro analysis of TCR-transfer into T cells from HIV-1-infected patients in various stages of disease and from healthy controls. Methods: Peripheral blood mononuclear cells from 16 HIV-1-infected patients (nine HLA-A*02-positive, seven HLA-A*02-negative) and from five healthy controls were electroporated with mRNA-constructs encoding TCRs specific for the HLA-A*02/HIV-1gag p17 epitope SLYNTVATL (SL9). Functionality of the TCRs was measured by gamma IFN-ELISpot assays. Results: SL9/TCR transfection into peripheral blood mononuclear cells from both HLA-A*02-positive and HLA-A*02-negative HIV-1-infected patients and from healthy blood donors reprogramed T cells for recognition of SL9-presenting HLA-A*02-positive cells in gIFN-ELISpot assays. SL9/TCR-transfer into T cells from an immunodeficient AIDS patient could induce recognition of SL9-expressing target cells only after reversion of T-cell dysfunction by antiretroviral therapy. Conclusion: The transfer of HIV-1-p17-specific TCRs into T cells is functional both in HIV-1-infected patients as well as in healthy blood donors. TCR-transfer is a promising method to boost the immune system against HIV-1. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options

Laura Gehrcken, Tatjana Sauerer, Niels Schaft, Jan Doerrie

Summary: Merkel cell carcinoma is a rare and aggressive skin cancer, predominantly caused by Merkel cell polyomavirus or UV light. Checkpoint inhibitor therapies like PD-1/PD-L1 inhibitors show promise in treating metastatic MCC, but some patients do not respond due to diverse immune-related adverse events caused by various mechanisms.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Biochemistry & Molecular Biology

A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells

Naomi C. Bosch, Lena-Marie Martin, Caroline J. Voskens, Carola Berking, Barbara Seliger, Gerold Schuler, Niels Schaft, Jan Doerrie

Summary: NK cells play a crucial role in tumor cell rejection, and activating NK cells along with other immune cells can lead to a more comprehensive cellular response. Dendritic cells are capable of enhancing immune responses by activating NK cells and producing IL-12, while IL-15 serves as an important NK cell activator as well.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Biochemistry & Molecular Biology

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

Stefanie Hoyer, Valentina Eberlein, Gerold Schuler, Carola Berking, Lucie Heinzerling, Niels Schaft, Jan Doerrie

Summary: This study investigated the impact of BRAFi/MEKi on the maturation of monocyte-derived dendritic cells (moDCs) and their interaction with T cells. The findings showed that these inhibitors altered cytokine secretion and surface marker expression of DCs, leading to lower activation markers and cytokine secretion in T cells during antigen-specific stimulation。

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Virology

Breaking Entry-and Species Barriers: LentiBOOST(R) Plus Polybrene Enhances Transduction Efficacy of Dendritic Cells and Monocytes by Adenovirus 5

Astrid Strack, Andrea Deinzer, Christian Thirion, Silke Schroedel, Jan Doerrie, Tatjana Sauerer, Alexander Steinkasserer, Ilka Knippertz

Summary: In this study, the use of LentiBOOST(R)/Polybrene significantly improved the transduction rate of HAdV-5 in various immune cells in both mice and humans, without affecting their phenotype and function.

VIRUSES-BASEL (2022)

Article Immunology

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma

Elias A. T. Koch, Niels Schaft, Mirko Kummer, Carola Berking, Gerold Schuler, Kenichiro Hasumi, Jan Doerrie, Beatrice Schuler-Thurner

Summary: Uveal melanoma is a rare disease with poor response to traditional therapies. Researchers designed a trial using personalized dendritic cell vaccines to activate the immune system and potentially improve clinical outcomes.

FRONTIERS IN IMMUNOLOGY (2022)

Article Cell Biology

Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization

Xin Lai, Christine Keller, Guido Santos, Niels Schaft, Jan Doerrie, Julio Vera

Summary: Dendritic cells (DCs) can be used for therapeutic vaccination against cancer. Computational modeling can improve our understanding of the molecular mechanisms underlying DC-induced CTL response and help identify new strategies to improve therapeutic DC vaccination for cancer.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Review Biochemistry & Molecular Biology

Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases

Amke C. Beenen, Tatjana Sauerer, Niels Schaft, Jan Doerrie

Summary: PD-L1 is a transmembrane protein that plays a crucial role in immune modulation. It interacts with its receptor PD-1 to induce an immune-suppressive signal, regulating the activity of T cells and other effector cells. Apart from its application in cancer therapy, the role of PD-L1 in healthy tissue and non-cancerous diseases has been largely overlooked.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells

Dennis Christoph Harrer, Charlotte Schenkel, Carola Berking, Wolfgang Herr, Hinrich Abken, Jan Doerrie, Niels Schaft

Summary: In this study, the FDA-approved drug decitabine was used to upregulate the expression of CSPG4 in ovarian carcinoma cells, expanding the repertoire of targetable antigens. The results demonstrated the potential of CSPG4 as an inducible antigen for CAR-T cells in ovarian cancer.

CANCERS (2022)

Article Multidisciplinary Sciences

XCR1 expression distinguishes human conventional dendritic cell type 1 with full effector functions from their immediate

Lukas Heger, Lukas Hatscher, Chunguang Liang, Christian H. K. Lehmann, Lukas Amon, Jennifer J. Luehr, Tomasz Kaszubowski, Rayk Nzirorera, Niels Schaft, Jan Doerrie, Pascal Irrgang, Matthias Tenbusch, Meik Kunz, Eileen Socher, Stella E. Autenrieth, Ariawan Purbojo, Horia Sirbu, Arndt Hartmann, Christoph Alexiou, Robert Cesnjevar, Diana Dudziak

Summary: Dendritic cells (DCs) are important regulators of immune responses, and can be classified into different types. One type of human DCs, called cDC1, can be distinguished based on the expression of XCR1. XCR1(+) cDC1 have a pre-activated phenotype, secrete high levels of inflammatory cytokines and chemokines upon stimulation, and are efficient in activating NK cells as well as inhibiting replication of Influenza A virus. XCR1(-) cDC1, on the other hand, may represent a late immediate precursor of cDC1 and secrete comparable level of inflammatory cytokines after differentiation.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Immunology

Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality

Felix Pfister, Jan Doerrie, Niels Schaft, Vera Buchele, Harald Unterweger, Lucas R. Carnell, Patrick Schreier, Rene Stein, Marketa Kubankova, Jochen Guck, Holger Hackstein, Christoph Alexiou, Christina Janko

Summary: The influence of superparamagnetic iron oxide nanoparticles (SPIONs) on primary human T cells and their potential for magnetically targeted adoptive T cell therapy were investigated in this study. Results showed that SPION-loading did not affect the mechanics and functionality of T cells, indicating its potential for magnetically enriching T cells in solid tumors.

FRONTIERS IN IMMUNOLOGY (2023)

Review Biochemistry & Molecular Biology

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy

Dennis Christoph Harrer, Jan Doerrie, Niels Schaft

Summary: The development of CAR-T cells has revolutionized cancer immunotherapy, but there are challenges such as relapse or refractory disease in some patients, especially those with solid tumors. Obstacles to successful CAR-T cell therapy include antigen shutdown and CAR-T cell dysfunctionality. This review highlights different approaches, including combining CAR-T cells with drugs, to overcome these obstacles and improve the efficacy of CAR-T cell therapy in both hematological malignancies and solid tumors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

No Data Available